Literature DB >> 32344168

Early diagnosis and rapid isolation: response to COVID-19 outbreak in Korea.

K R Peck1.   

Abstract

Entities:  

Keywords:  COVID-19; Control; Diagnosis; Isolation; Pandemic

Mesh:

Year:  2020        PMID: 32344168      PMCID: PMC7182747          DOI: 10.1016/j.cmi.2020.04.025

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


× No keyword cloud information.
We couldn't know that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) would be very different from SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV) even when it was identified as the pathogen of pneumonia of unknown aetiology spreading in China. We initially responded to coronavirus disease 2019 (COVID-19) in the same way as we did against SARS and MERS. The overall case fatality rate of COVID-19 is lower than that of SARS. However, because patients with COVID-19 shed virus at the early stage with mild symptoms, our efforts to contain COVID-19 have failed. Since the first COVID-19 case was identified in Korea on January 20, 2020, we have experienced an explosive outbreak related to a religious group in the city of Daegu and North Gyeongsang Province [1]. Daegu is Korea's fourth largest city, with a population of 2 500 000, and is surrounded by North Gyeongsang Province. More than 1000 persons of the religious group attended worship services, kneeling on the floor in a relatively small space for the congregation on February 8 and 15. Since February 18, when the first case related to that religious group was identified, the highest number of new cases in a day reached 813 on February 29 (Fig. 1 ) [2]. Since then, the daily number of new cases started to decrease and became <100 on March 15. Remaining concerns are persistent small-cluster outbreaks and an increasing number of imported cases from outside Korea. Currently, many countries in the world are suffering from surging outbreaks. Although principal emergency strategies are common [3], COVID-19 is quite different from other known diseases, and we have to share our experience and knowledge to overcome this COVID-19 pandemic.
Fig. 1

Timeline of cases with COVID-19 in Korea (modified from [2]). DT, drive-through screening; LTC, Life Treatment Centre.

Timeline of cases with COVID-19 in Korea (modified from [2]). DT, drive-through screening; LTC, Life Treatment Centre. First, rapid diagnosis and rapid isolation is the key to the prevention of transmission. Korea Centres for Disease Control and Prevention (KCDC) and commercial diagnostic companies started to set up a real-time RT-PCR assay to detect SARS-CoV-2 as soon as the genetic sequences were released. KCDC wanted to boost large-scale DNA analysis capabilities after having experienced the 2015 MERS outbreak. By early March, Korea was capable of running as many as 20 000 tests a day, and a total of 433 211 tests have been performed as of April 3. Rapidly implemented diagnostic techniques enabled proactive screening of contacts and early diagnosis. The relatively shorter period of symptom onset to diagnosis of COVID-19 (7 days in Korea versus 10 days in China) has led to the rapid isolation of patients and a reduction in further transmission [1]. With an increasing number of suspected and/or symptomatic patients to be tested for COVID-19, there has been a need for a safe and efficient screening system. Procedures for obtaining nasopharyngeal swabs, recommended for the detection of SARS-CoV-2, are considered as aerosol-generating procedures, and require specific facilities such as airborne infection isolation rooms (AIIRs) which need disinfection and ventilation between patients. Because very limited numbers of patients could be tested in conventional AIIRs, drive-through (DT) screening centres have been implemented to facilitate specimen collections by hospitals and local authorities [4]. Because the entire procedure takes about 10 min per person, and several persons can be served at different steps at the same time, the testing capacity reaches over 100 samplings per day. DT screening centres contributed to the early diagnosis of masses of patients without delay. Second, patient triage and prioritization of medical resources are essential for the prevention of a surge during an outbreak. The shortage of healthcare services has become more severe during this COVID-19 pandemic situation. As well as the essential equipment—including hand sanitizers, N95 respirators, and ventilators—hospital beds are lacking. The surge of the outbreak has in many countries led to the breakdown of healthcare systems and an increase in case fatality rates. Although COVID-19 starts with mild symptoms, about 15% of patients with COVID-19 progress to a severe condition, and 5% require ICU care within 5–7 days [5]. They are hospitalized for several weeks until recovery. The hospital beds would quickly be saturated with mild or moderate cases in the early phase of massive outbreak situations. It would be difficult to find beds for patients diagnosed later, and some of them could experience aggravation during home isolation as happened in Daegu [1]. Early diagnosis and adequate initial management are crucial for a better prognosis of COVID-19, because no specific treatment is available. It is less likely that the hospital systems are sufficiently prepared for all the patients with COVID-19, even in the countries with high-performing health systems. The rapidly deteriorating patients will eventually have adverse outcomes if they don't receive appropriate supportive management in time. Therefore, we established the systems to triage patients and prepared facilities for patients with variable disease severity. Third, the nation should prepare for other types of care centres beyond hospital beds. Moderately or severely ill patients need medical management or intensive care in hospitals, while mildly ill patients can stay at home. Because patients with mild symptoms are shedding high viral loads in the early phase of the disease [6], they can easily transmit the virus to their household contacts. Therefore, these asymptomatic or mild patients should be isolated in isolation-and-care centres. In Korea, accommodation facilities were converted to isolation-and-care facilities and named Life Treatment Centres (LTCs) by the KCDC [7]. The first centre was opened on March 2, and as of March 26 a total of 18 centres could accommodate about 4000 people in Korea. Not only were public facilities utilized, but also private facilities were provided voluntarily and operated by matching hospitals. These types of isolation facilities would be useful to monitor the aggravation of the symptoms of patients and to prevent further transmission to others. Although this could be beneficial for patients' outcomes and disease containment, it might be challenging to operate because human resources, usually lacking in the crisis, are needed. As strategies to reduce the requirement for human resources, information technologies (such as mobile phone applications) were implemented to monitor patients. Fourth, a contingency plan should be prepared to enhance the capacity for critical care. An enormous number of patients with COVID-19 overwhelmed the capacity of isolation beds and ICU beds since late February, although there were more than 5500 beds in six tertiary-care hospitals in Daegu. Makeshift wards have been dedicated for patients with COVID-19 in hospitals, and public hospitals have been transformed for COVID-19 care only. Temporary AIIRs using mobile machines generating negative air pressure and temporary ICU beds have been prepared. Volunteering doctors and nurses have been taking care of the patients. Military personnel and ambulance workers were sent to Daegu from other regions. In addition, some of the patients were transferred to hospitals in other regions. Hospitals for COVID-19 care have been designated for the efficient use of limited resources. The continuous communication and collaboration between professional societies with health authorities and local authorities are the important component for the efficient and rapid response to the health crisis. The Korean Society of Infectious Disease formed the committee for COVID-19 response on January 27 and organized the multidisciplinary committee with ten professional societies, including the Korean Society of Epidemiology, the Korean Society of Healthcare-Associated Infection Control and Prevention, the Korean Society of Critical Care Medicine, and the Korean Society of Emergency Medicine on February 4. This multidisciplinary committee have had weekly meetings with the KCDC and Ministry of Health and Welfare. We advised installing a DT system and implementing strategies to triage patients and prepare facilities for patients with variable severity including LTCs. In Korea, from the painful experiences in the 2015 MERS outbreak, the preparedness for emerging infectious diseases (EIDs) has advanced in terms of diagnostic capacities, transparent risk communications, and the cooperation of people. Although we had built more isolation units in hospitals, we now realize that those are not sufficient to overcome this massive epidemic. The threat of EIDs would continue, and we do not know how and when it would come. Singapore, Taiwan and Hong Kong, having experienced the SARS outbreak, are well prepared for EIDs, and are responding efficiently against COVID-19. Investigation into the building of National Hospitals for Infectious Diseases and for specialists to take care of outbreaks should be top priority for our future safety. Since the first outbreak in China, mankind is suffering, and the loss is devastating. However, we are gathering wisdom, best knowledge, and intellectual reasoning with state-of-the-art science to overcome this outbreak. We may have to live with COVID-19 for some time. While we are responding, we have to prepare the next sustainable strategies along with our lives.

Transparency declaration

There are no potential conflicts of interest relevant to this article. No external funding was received.
  7 in total

1.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.

Authors:  Kelvin Kai-Wang To; Owen Tak-Yin Tsang; Wai-Shing Leung; Anthony Raymond Tam; Tak-Chiu Wu; David Christopher Lung; Cyril Chik-Yan Yip; Jian-Piao Cai; Jacky Man-Chun Chan; Thomas Shiu-Hong Chik; Daphne Pui-Ling Lau; Chris Yau-Chung Choi; Lin-Lei Chen; Wan-Mui Chan; Kwok-Hung Chan; Jonathan Daniel Ip; Anthony Chin-Ki Ng; Rosana Wing-Shan Poon; Cui-Ting Luo; Vincent Chi-Chung Cheng; Jasper Fuk-Woo Chan; Ivan Fan-Ngai Hung; Zhiwei Chen; Honglin Chen; Kwok-Yung Yuen
Journal:  Lancet Infect Dis       Date:  2020-03-23       Impact factor: 25.071

2.  Emergent Strategies for the Next Phase of COVID-19.

Authors:  Kyungmin Huh; Hyoung Shik Shin; Kyong Ran Peck
Journal:  Infect Chemother       Date:  2020-02-25

3.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

4.  Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020.

Authors: 
Journal:  J Korean Med Sci       Date:  2020-03-30       Impact factor: 2.153

5.  Out-of-Hospital Cohort Treatment of Coronavirus Disease 2019 Patients with Mild Symptoms in Korea: an Experience from a Single Community Treatment Center.

Authors:  Peong Gang Park; Chang Hyup Kim; Yoon Heo; Tae Suk Kim; Chan Woo Park; Choong Hyo Kim
Journal:  J Korean Med Sci       Date:  2020-04-06       Impact factor: 2.153

6.  Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020.

Authors: 
Journal:  J Korean Med Sci       Date:  2020-03-16       Impact factor: 2.153

7.  Drive-Through Screening Center for COVID-19: a Safe and Efficient Screening System against Massive Community Outbreak.

Authors:  Ki Tae Kwon; Jae Hoon Ko; Heejun Shin; Minki Sung; Jin Yong Kim
Journal:  J Korean Med Sci       Date:  2020-03-23       Impact factor: 2.153

  7 in total
  22 in total

1.  COVID-19 trends, public restrictions policies and vaccination status by economic ranking of countries: a longitudinal study from 110 countries.

Authors:  Myung-Bae Park; Chhabi Lal Ranabhat
Journal:  Arch Public Health       Date:  2022-08-24

2.  Clinical application of rapid diagnostic test kit for SARS-CoV-2 antibodies into the field of patient care.

Authors:  Jae-Hoon Ko; Eun-Jeong Joo; Sung-Han Kim; Yae-Jean Kim; Kyungmin Huh; Sun Young Cho; Cheol-In Kang; Doo Ryeon Chung; Eun-Suk Kang; Kyong Ran Peck
Journal:  J Microbiol Immunol Infect       Date:  2020-07-10       Impact factor: 4.399

3.  Increasing Age, the Existence of Comorbidities, and Corticosteroid Treatment in Combination With Antiviral Therapy Prolongs the Recovery of SARS-COV-2-Infected Patients, Measured as the Conversion From Positive to Negative rtPCR: A 239 Patients' Retrospective Study.

Authors:  Sheng Zhu; Yaxiong Huang; Wei Tang; Andreas K Nussler; Fang Zheng
Journal:  Front Med (Lausanne)       Date:  2020-11-12

Review 4.  Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers.

Authors:  Mohamed Abbas; Tomás Robalo Nunes; Romain Martischang; Walter Zingg; Anne Iten; Didier Pittet; Stephan Harbarth
Journal:  Antimicrob Resist Infect Control       Date:  2021-01-06       Impact factor: 4.887

5.  Differences in seroprevalence between epicenter and non-epicenter areas of the COVID-19 outbreak in South Korea.

Authors:  Hye Won Jeong; Hyun-Ha Chang; Eun Ji Kim; Yu Kyung Kim; Se-Mi Kim; Eun-Ha Kim; Young-Il Kim; Mark Anthony B Casel; Seong-Gyu Kim; Rare Rollon; Seung-Gyu Jang; Kwang-Min Yu; Hee-Sung Kim; Hee Sue Park; Su-Jin Park; Yong-Dae Kim; Eung-Gook Kim; Young Ki Choi
Journal:  J Microbiol       Date:  2021-04-28       Impact factor: 3.422

6.  A prognostic dynamic model applicable to infectious diseases providing easily visualized guides: a case study of COVID-19 in the UK.

Authors:  Yuxuan Zhang; Chen Gong; Dawei Li; Zhi-Wei Wang; Shengda D Pu; Alex W Robertson; Hong Yu; John Parrington
Journal:  Sci Rep       Date:  2021-04-16       Impact factor: 4.996

7.  Home or Cabin: Community Care for Coronavirus Disease 2019.

Authors:  Nisha Andany; Nick Daneman
Journal:  Chest       Date:  2020-09       Impact factor: 9.410

8.  Clinical Characteristics of COVID-19: Clinical Dynamics of Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection Detected by Early Active Surveillance.

Authors:  Hyeon Jeong Suh; Deok Hee Kim; Eun Young Heo; Hyun Woo Lee; Jung Kyu Lee; Chang Seop Lee; Mijeong Kim; Yong Duk Jeon; Jin Won Chung; Young Keun Kim; Pyo Jin Shin; Mi Suk Lee; Jin Suk Kang; Myung Jin Lee; Baek Nam Kim; Sang Won Park
Journal:  J Korean Med Sci       Date:  2020-08-17       Impact factor: 2.153

9.  A Systematic Narrative Review of Comprehensive Preparedness Strategies of Healthcare Resources for a Large Resurgence of COVID-19 Nationally, with Local or Regional Epidemics: Present Era and Beyond.

Authors:  Young Kyung Yoon; Jacob Lee; Sang Il Kim; Kyong Ran Peck
Journal:  J Korean Med Sci       Date:  2020-11-16       Impact factor: 2.153

Review 10.  Recommendations for the management of patients with systemic rheumatic diseases during the coronavirus disease pandemic.

Authors:  Mi Ryoung Seo; Ji-Won Kim; Eun-Jung Park; Seung Min Jung; Yoon-Kyoung Sung; Hyungjin Kim; Gunwoo Kim; Hyun-Sook Kim; Myeung-Su Lee; Jisoo Lee; Ji An Hur; Bum Sik Chin; Joong Sik Eom; Han Joo Baek
Journal:  Korean J Intern Med       Date:  2020-09-15       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.